You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBexarotene
Accession NumberDB00307  (APRD00114)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. [Wikipedia]
Structure
Thumb
Synonyms
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
Bexaroten
Bexarotène
Bexarotene
Bexaroteno
Bexarotenum
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
Targretyn
Targrexin
External Identifiers
  • LG 100069
  • LGD 1069
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BexaroteneCapsule, liquid filled75 mg/1OralOceanside Pharmaceuticals1999-12-29Not applicableUs
TargretinCapsule, liquid filled75 mg/1OralEisai Inc.1999-12-29Not applicableUs
TargretinGel1 g/100gTopicalEisai Inc.2000-06-28Not applicableUs
TargretinGel1 g/100gTopicalValeant Pharmaceuticals North America LLC2000-06-28Not applicableUs
TargretinCapsule75 mgOralEisai Ltd2001-03-29Not applicableEu
TargretinCapsule, liquid filled75 mg/1OralValeant Pharmaceuticals North America LLC1999-12-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BexaroteneCapsule, liquid filled75 mg/1OralMylan Pharmaceuticals Inc.2015-07-09Not applicableUs
BexaroteneCapsule, liquid filled75 mg/1OralMylan Institutional Inc.2016-04-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIA61RXM4375
CAS number153559-49-0
WeightAverage: 348.4779
Monoisotopic: 348.20893014
Chemical FormulaC24H28O2
InChI KeyNAVMQTYZDKMPEU-UHFFFAOYSA-N
InChI
InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
IUPAC Name
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
SMILES
CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C
Pharmacology
IndicationUsed orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
Structured Indications
PharmacodynamicsBexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models.
Mechanism of actionBexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.
TargetKindPharmacological actionActionsOrganismUniProt ID
Retinoic acid receptor RXR-alphaProteinyes
agonist
HumanP19793 details
Retinoic acid receptor RXR-betaProteinyes
agonist
HumanP28702 details
Retinoic acid receptor RXR-gammaProteinyes
agonist
HumanP48443 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding>99%
MetabolismNot Available
Route of eliminationUrinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of administered dose).
Half life7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Bexarotene.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Bexarotene.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Bexarotene.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bexarotene.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Bexarotene.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Bexarotene.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Bexarotene.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Bexarotene.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Bexarotene.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Bexarotene.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Bexarotene.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Bexarotene.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Bexarotene.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Bexarotene.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Bexarotene.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Bexarotene.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Bexarotene.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Bexarotene.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Bexarotene.Approved
AmiodaroneThe metabolism of Bexarotene can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Bexarotene.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Bexarotene.Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Bexarotene.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Bexarotene.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Bexarotene.Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Bexarotene.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Bexarotene.Approved, Investigational
AprepitantThe serum concentration of Bexarotene can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Bexarotene.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Bexarotene.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Bexarotene.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Bexarotene.Approved, Withdrawn
AtazanavirThe metabolism of Bexarotene can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Bexarotene can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Bexarotene.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Bexarotene.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Bexarotene.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Bexarotene.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Bexarotene.Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Bexarotene.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Bexarotene.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Bexarotene.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Bexarotene.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Bexarotene.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Bexarotene.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Bexarotene.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Bexarotene.Approved
BoceprevirThe metabolism of Bexarotene can be decreased when combined with Boceprevir.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Bexarotene.Approved, Investigational
BosentanThe serum concentration of Bexarotene can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Bexarotene.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bexarotene.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Bexarotene.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Bexarotene.Approved
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Bexarotene.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Bexarotene.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Bexarotene.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Bexarotene.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Bexarotene.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Bexarotene.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Bexarotene.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Bexarotene.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Bexarotene.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bexarotene.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Bexarotene.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Bexarotene.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Bexarotene.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Bexarotene.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Bexarotene.Approved
CapecitabineThe metabolism of Bexarotene can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Bexarotene can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Bexarotene.Approved
CarboplatinThe serum concentration of Bexarotene can be increased when it is combined with Carboplatin.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Bexarotene.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Bexarotene.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Bexarotene.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Bexarotene.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Bexarotene.Approved, Vet Approved
CeritinibThe serum concentration of Bexarotene can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Bexarotene.Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Bexarotene.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Bexarotene.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Bexarotene.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Bexarotene.Withdrawn
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Bexarotene.Withdrawn
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Bexarotene.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Bexarotene.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Bexarotene.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Bexarotene.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Bexarotene.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Bexarotene.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Bexarotene.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Bexarotene.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Bexarotene.Approved
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Bexarotene.Approved
ClemastineThe metabolism of Bexarotene can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Bexarotene.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Bexarotene.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Bexarotene.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Bexarotene.Approved
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Bexarotene.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Bexarotene.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Bexarotene.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Bexarotene.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Bexarotene.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Bexarotene.Approved, Illicit
ClotrimazoleThe metabolism of Bexarotene can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bexarotene is combined with Clozapine.Approved
CobicistatThe metabolism of Bexarotene can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Bexarotene.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Bexarotene.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Bexarotene.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Bexarotene.Approved
ConivaptanThe serum concentration of Bexarotene can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bexarotene.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Bexarotene.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Bexarotene.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bexarotene.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Bexarotene.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Bexarotene.Approved, Investigational
DabrafenibThe serum concentration of Bexarotene can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Bexarotene.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Bexarotene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Bexarotene.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Bexarotene.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Bexarotene.Approved, Investigational
DarunavirThe metabolism of Bexarotene can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Bexarotene.Approved
DasatinibThe serum concentration of Bexarotene can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Bexarotene.Approved
DeferasiroxThe serum concentration of Bexarotene can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bexarotene can be decreased when combined with Delavirdine.Approved
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Bexarotene.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bexarotene.Approved
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Bexarotene.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Bexarotene.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bexarotene.Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Bexarotene.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bexarotene.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Bexarotene.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Bexarotene.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Bexarotene.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Bexarotene.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Bexarotene.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Bexarotene.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Bexarotene.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Bexarotene.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bexarotene.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Bexarotene.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bexarotene.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Bexarotene.Approved
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Bexarotene.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Bexarotene.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Bexarotene.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bexarotene.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Bexarotene.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Bexarotene.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Bexarotene.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Bexarotene.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Bexarotene.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Bexarotene.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Bexarotene.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Bexarotene.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Bexarotene.Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Bexarotene.Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Bexarotene.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Bexarotene.Approved, Investigational
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Bexarotene.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Bexarotene.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Bexarotene.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Bexarotene.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Bexarotene.Approved, Vet Approved
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Bexarotene.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Bexarotene.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Bexarotene.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Bexarotene.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bexarotene.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Bexarotene.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Bexarotene.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Bexarotene.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Bexarotene.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Bexarotene.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Bexarotene can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Bexarotene.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Bexarotene.Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Bexarotene.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Bexarotene.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Bexarotene.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Bexarotene.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Bexarotene.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Bexarotene.Approved
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Bexarotene.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bexarotene.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Bexarotene.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Bexarotene.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Bexarotene.Approved
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Bexarotene.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Bexarotene.Approved, Investigational
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Bexarotene.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Bexarotene.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Bexarotene.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Bexarotene.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Bexarotene.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Bexarotene.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Bexarotene.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Bexarotene.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Bexarotene.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Bexarotene.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Bexarotene.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Bexarotene.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Bexarotene.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Bexarotene.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Bexarotene.Approved
FloxuridineThe metabolism of Bexarotene can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Bexarotene can be decreased when combined with Fluconazole.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Bexarotene.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Bexarotene.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Bexarotene.Approved
FluorouracilThe metabolism of Bexarotene can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Bexarotene.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Bexarotene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bexarotene.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Bexarotene.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Bexarotene.Approved
FluvoxamineThe metabolism of Bexarotene can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Bexarotene.Approved
FosaprepitantThe serum concentration of Bexarotene can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Bexarotene can be increased when combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Bexarotene.Approved, Investigational
Fusidic AcidThe serum concentration of Bexarotene can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Bexarotene.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Bexarotene.Approved, Investigational
GemfibrozilThe serum concentration of Bexarotene can be increased when it is combined with Gemfibrozil.Approved
GemfibrozilThe metabolism of Bexarotene can be decreased when combined with Gemfibrozil.Approved
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Bexarotene.Approved
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Bexarotene.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Bexarotene.Approved
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Bexarotene.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Bexarotene.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Bexarotene.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Bexarotene.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Bexarotene.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Bexarotene.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Bexarotene.Approved, Vet Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Bexarotene.Withdrawn
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Bexarotene.Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Bexarotene.Approved
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Bexarotene.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Bexarotene.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Bexarotene.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Bexarotene.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Bexarotene.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Bexarotene.Approved
IdelalisibThe serum concentration of Bexarotene can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Bexarotene resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Bexarotene.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Bexarotene.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Bexarotene.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Bexarotene.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Bexarotene.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Bexarotene.Approved
IndinavirThe metabolism of Bexarotene can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bexarotene.Approved
IrbesartanThe metabolism of Bexarotene can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Bexarotene.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Bexarotene.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bexarotene.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bexarotene.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Bexarotene.Approved
ItraconazoleThe metabolism of Bexarotene can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Bexarotene.Approved
IvacaftorThe serum concentration of Bexarotene can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Bexarotene.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Bexarotene.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Bexarotene.Approved
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Bexarotene.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Bexarotene.Approved
KetoconazoleThe metabolism of Bexarotene can be decreased when combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Bexarotene.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Bexarotene.Investigational
LeflunomideThe metabolism of Bexarotene can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Bexarotene.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Bexarotene.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Bexarotene.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Bexarotene.Approved
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Bexarotene.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Bexarotene.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Bexarotene.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Bexarotene.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Bexarotene.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Bexarotene.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Bexarotene.Approved
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Bexarotene.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Bexarotene.Approved
LopinavirThe metabolism of Bexarotene can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Bexarotene.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Bexarotene.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Bexarotene.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Bexarotene.Approved, Investigational
LuliconazoleThe serum concentration of Bexarotene can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bexarotene can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Bexarotene.Approved
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Bexarotene.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Bexarotene.Investigational
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Bexarotene.Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Bexarotene.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Bexarotene.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Bexarotene.Approved, Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Bexarotene.Approved, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bexarotene.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Bexarotene.Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Bexarotene.Approved, Vet Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Bexarotene.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Bexarotene.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bexarotene.Withdrawn
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Bexarotene.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Bexarotene.Experimental
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Bexarotene.Experimental
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Bexarotene.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Bexarotene.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Bexarotene.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Bexarotene.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Bexarotene.Approved
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Bexarotene.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Bexarotene.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Bexarotene.Approved
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Bexarotene.Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Bexarotene.Approved, Illicit
MifepristoneThe serum concentration of Bexarotene can be increased when it is combined with Mifepristone.Approved, Investigational
MinocyclineThe risk or severity of adverse effects can be increased when Minocycline is combined with Bexarotene.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Bexarotene.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Bexarotene.Approved
MitotaneThe serum concentration of Bexarotene can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Bexarotene.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Bexarotene.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Bexarotene.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bexarotene.Approved, Investigational
NafcillinThe serum concentration of Bexarotene can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Bexarotene.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Bexarotene.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Bexarotene.Approved, Investigational
NefazodoneThe metabolism of Bexarotene can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bexarotene can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Bexarotene can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bexarotene can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Bexarotene can be decreased when combined with Nicardipine.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Bexarotene.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Bexarotene.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Bexarotene.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Bexarotene.Approved
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Bexarotene.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Bexarotene.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Bexarotene.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Bexarotene.Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Bexarotene.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Bexarotene.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Bexarotene.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Bexarotene.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Bexarotene.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Bexarotene.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Bexarotene.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Bexarotene.Approved
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Bexarotene.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Bexarotene.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Bexarotene.Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Bexarotene.Approved
OsimertinibThe serum concentration of Bexarotene can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Bexarotene.Approved
OuabainOuabain may decrease the cardiotoxic activities of Bexarotene.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Bexarotene.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Bexarotene.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Bexarotene.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxytetracycline is combined with Bexarotene.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bexarotene.Approved, Vet Approved
PaclitaxelThe serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Bexarotene.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Bexarotene.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Bexarotene.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Bexarotene.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Bexarotene.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Bexarotene.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Bexarotene.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Bexarotene.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Bexarotene.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Bexarotene.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Bexarotene.Approved
PentobarbitalThe metabolism of Bexarotene can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Bexarotene.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Bexarotene.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Bexarotene.Approved
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Bexarotene.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Bexarotene.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Bexarotene.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Bexarotene.Withdrawn
PhenobarbitalThe metabolism of Bexarotene can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Bexarotene.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Bexarotene.Approved
PhenytoinThe metabolism of Bexarotene can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Bexarotene.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Bexarotene.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Bexarotene.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Bexarotene.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Bexarotene.Approved
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Bexarotene.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Bexarotene.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Bexarotene.Approved
PosaconazoleThe metabolism of Bexarotene can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Bexarotene.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Bexarotene.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Bexarotene.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Bexarotene.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Bexarotene.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Bexarotene.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Bexarotene.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Bexarotene.Approved
PrimidoneThe metabolism of Bexarotene can be increased when combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Bexarotene.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Bexarotene.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Bexarotene.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Bexarotene.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Bexarotene.Approved
PyrimethamineThe metabolism of Bexarotene can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Bexarotene.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Bexarotene.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Bexarotene.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Bexarotene.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Bexarotene.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Bexarotene.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Bexarotene.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Bexarotene.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Bexarotene.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Bexarotene.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Bexarotene.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Bexarotene.Approved
RifabutinThe metabolism of Bexarotene can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bexarotene can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bexarotene can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Bexarotene.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Bexarotene.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Bexarotene.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Bexarotene.Approved, Investigational
RitonavirThe metabolism of Bexarotene can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bexarotene.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Bexarotene.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Bexarotene.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Bexarotene.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Bexarotene.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Bexarotene.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Bexarotene.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Bexarotene.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Bexarotene.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Bexarotene.Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Bexarotene.Approved
SaquinavirThe metabolism of Bexarotene can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Bexarotene.Approved
SecobarbitalThe metabolism of Bexarotene can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Bexarotene.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Bexarotene.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Bexarotene.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Bexarotene.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Bexarotene.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Bexarotene.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Bexarotene.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Bexarotene.Approved
SiltuximabThe serum concentration of Bexarotene can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Bexarotene.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Bexarotene.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Bexarotene.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Bexarotene.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Bexarotene.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Bexarotene.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Bexarotene.Approved
St. John's WortThe serum concentration of Bexarotene can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Bexarotene can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Bexarotene.Approved, Investigational
SulfadiazineThe metabolism of Bexarotene can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Bexarotene.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Bexarotene.Approved
SulfisoxazoleThe metabolism of Bexarotene can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Bexarotene.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Bexarotene.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Bexarotene.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Bexarotene.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Bexarotene.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Bexarotene.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Bexarotene.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Bexarotene.Experimental
TelaprevirThe metabolism of Bexarotene can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Bexarotene can be decreased when combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Bexarotene.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Bexarotene.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Bexarotene.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Bexarotene.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Bexarotene.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Bexarotene.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Bexarotene.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Bexarotene.Approved, Vet Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Bexarotene.Approved
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Bexarotene.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Bexarotene.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Bexarotene.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Bexarotene.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Bexarotene.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Bexarotene.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Bexarotene.Approved, Investigational
TocilizumabThe serum concentration of Bexarotene can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Bexarotene.Approved, Investigational
TolbutamideThe metabolism of Bexarotene can be decreased when combined with Tolbutamide.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Bexarotene.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Bexarotene.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Bexarotene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Bexarotene.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Bexarotene.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bexarotene.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Bexarotene.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Bexarotene.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Bexarotene.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Bexarotene.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Bexarotene.Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Bexarotene.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Bexarotene.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Bexarotene.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Bexarotene.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Bexarotene.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Bexarotene.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Bexarotene.Approved
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Bexarotene.Investigational, Withdrawn
Valproic AcidThe metabolism of Bexarotene can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Bexarotene can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Bexarotene.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Bexarotene.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Bexarotene.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Bexarotene.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Bexarotene.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Bexarotene.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Bexarotene.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Bexarotene.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Bexarotene.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Bexarotene.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Bexarotene.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Bexarotene.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Bexarotene.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Bexarotene.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Bexarotene.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Vitamin A is combined with Bexarotene.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Bexarotene can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Bexarotene.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Bexarotene.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Bexarotene.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Bexarotene.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Bexarotene.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Bexarotene.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Bexarotene.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Bexarotene.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Bexarotene.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Bexarotene.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Bexarotene.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Bexarotene.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Bexarotene.Approved
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US5466861
General References
  1. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S: The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007 Sep;157(3):433-40. Epub 2007 Jun 6. [PubMed:17553039 ]
  2. Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E: A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007 Mar 15;13(6):1794-800. [PubMed:17363535 ]
  3. Smit JW, Stokkel MP, Pereira AM, Romijn JA, Visser TJ: Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab. 2007 Jul;92(7):2496-9. Epub 2007 Apr 17. [PubMed:17440015 ]
  4. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
  5. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  6. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]
External Links
ATC CodesL01XX25
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (40.2 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9022
Caco-2 permeable+0.794
P-glycoprotein substrateSubstrate0.6283
P-glycoprotein inhibitor INon-inhibitor0.5369
P-glycoprotein inhibitor IINon-inhibitor0.7182
Renal organic cation transporterNon-inhibitor0.8496
CYP450 2C9 substrateNon-substrate0.7722
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6786
CYP450 1A2 substrateNon-inhibitor0.8171
CYP450 2C9 inhibitorNon-inhibitor0.8724
CYP450 2D6 inhibitorInhibitor0.5589
CYP450 2C19 inhibitorInhibitor0.8351
CYP450 3A4 inhibitorNon-inhibitor0.8138
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6458
Ames testNon AMES toxic0.8592
CarcinogenicityNon-carcinogens0.7898
BiodegradationNot ready biodegradable0.933
Rat acute toxicity2.2119 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9703
hERG inhibition (predictor II)Non-inhibitor0.9034
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eisai inc
Packagers
Dosage forms
FormRouteStrength
Capsule, liquid filledOral75 mg/1
CapsuleOral75 mg
GelTopical1 g/100g
Prices
Unit descriptionCostUnit
Targretin 75 mg capsule38.0USD capsule
Targretin 75 mg softgel36.54USD softget capsule
Targretin 1% gel30.08USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5780676 No1995-07-142015-07-14Us
US5962731 No1996-10-052016-10-05Us
US6043279 No1995-04-222012-04-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000149 mg/mLALOGPS
logP6.86ALOGPS
logP6.94ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)4.07ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity117.12 m3·mol-1ChemAxon
Polarizability40.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassRetinoids
Direct ParentRetinoids
Alternative Parents
Substituents
  • Bexarotene
  • Bisabolane sesquiterpenoid
  • Sesquiterpenoid
  • Tetralin
  • Phenylpropene
  • Benzoic acid
  • Benzoic acid or derivatives
  • Styrene
  • Benzoyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXR...
Gene Name:
RXRA
Uniprot ID:
P19793
Molecular Weight:
50810.835 Da
References
  1. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
  2. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. [PubMed:18765556 ]
  3. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007 May 1;67(9):4425-33. [PubMed:17483357 ]
  4. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28. [PubMed:17008586 ]
  5. Yen WC, Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005 May;4(5):824-34. [PubMed:15897247 ]
  6. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  7. Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):210-5. [PubMed:14700480 ]
  8. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 2005 Jan;10(1):22-33. [PubMed:15632250 ]
  9. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (By similarity). Specifically bin...
Gene Name:
RXRB
Uniprot ID:
P28702
Molecular Weight:
56921.38 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. [PubMed:18765556 ]
  4. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007 May 1;67(9):4425-33. [PubMed:17483357 ]
  5. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28. [PubMed:17008586 ]
  6. Yen WC, Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005 May;4(5):824-34. [PubMed:15897247 ]
  7. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  8. Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):210-5. [PubMed:14700480 ]
  9. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 2005 Jan;10(1):22-33. [PubMed:15632250 ]
  10. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]
  11. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXR...
Gene Name:
RXRG
Uniprot ID:
P48443
Molecular Weight:
50870.72 Da
References
  1. Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. [PubMed:11702369 ]
  2. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. [PubMed:18765556 ]
  3. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007 May 1;67(9):4425-33. [PubMed:17483357 ]
  4. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28. [PubMed:17008586 ]
  5. Yen WC, Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005 May;4(5):824-34. [PubMed:15897247 ]
  6. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. [PubMed:16495926 ]
  7. Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):210-5. [PubMed:14700480 ]
  8. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 2005 Jan;10(1):22-33. [PubMed:15632250 ]
  9. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. [PubMed:15056048 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:42